Among 284 human immunodeficiency virus (HIV)-hepatitis B virus (HBV) coinfected adults starting tenofovir-based antiretroviral therapy (ART) in Zambia, median baseline CD4+ count was 202 cells/mm3 and 41.6% were hepatitis B e-antigen positive. Within 2 years of therapy, 29 (10.2%) participants experienced HBV functional cure (confirmed loss of hepatitis B surface antigen). In multivariable analysis, baseline CD4 count <350 cells/mm3, female sex, and lower baseline HBV deoxyribonucleic acid were associated with increased odds of functional cure. Immune recovery during HIV-HBV treatment with ART may drive higher rates of functional cure than during HBV monoinfection treatment. Understanding the mechanisms underlying this phenomenon could inform immunomodulatory therapies for HBV cure.

中文翻译：

---

赞比亚接受抗逆转录病毒治疗的人类免疫缺陷病毒-HBV 合并感染患者中乙型肝炎病毒 (HBV) 功能性治愈率较高。


在赞比亚开始接受替诺福韦抗逆转录病毒治疗 (ART) 的 284 名人类免疫缺陷病毒 (HIV)-乙型肝炎病毒 (HBV) 双重感染成人中，中位基线 CD4+ 计数为 202 个细胞/mm3，41.6% 为乙型肝炎 e 抗原阳性。治疗 2 年内，29 名 (10.2%) 参与者经历了 HBV 功能性治愈（确认乙型肝炎表面抗原消失）。在多变量分析中，基线 CD4 计数<350 细胞/mm3、女性和较低基线 HBV 脱氧核糖核酸与功能性治愈几率增加相关。与 HBV 单一感染治疗期间相比，采用 ART 治疗 HIV-HBV 期间的免疫恢复可能会带来更高的功能性治愈率。了解这种现象背后的机制可以为治疗乙型肝炎的免疫调节疗法提供信息。